The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc.’s anti-inflammation drug Dupixent to treat eczema in young children, the two companies said on Tuesday.
The U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Regeneron Pharmaceuticals Inc. said on Thursday the company would buy the global rights to the cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an upfront payment of $900 million.
The U.S. Food and Drug Administration (FDA) is on a mission to recover from the review lag seen through the early years of COVID-19 and has issued special designations for two treatments that could improve the lives of millions diagnosed with recurrent glioblastoma or hemophilia.
The U.S. health regulator put on hold a trial designed to evaluate switching the prescription-only erectile dysfunction drug Cialis to an over-the-counter (OTC) treatment, French drugmaker Sanofi said on Monday.